Moderna said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in ...
Moderna's (MRNA) new COVID-19 shot, mRNA-1283, shows promising results in Phase 3 trials, with comparable efficacy and safety to its approved vaccine. Read more here.
CAMBRIDGE - Moderna announced Monday that its combination COVID and flu vaccine showed positive results in a late-stage trial ...
Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.
There are still multiple steps required before the shot would become available. Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to ...
, opens new tab said on Thursday its next-generation COVID-19 vaccine candidate showed it was not inferior in efficacy compared to its approved shot in a late-stage study. The experimental vaccine ...
Moderna said its combination flu and Covid shot met the goals of a pivotal late-stage trial, bringing the company one step closer to a more convenient jab that could help combat vaccine fatigue.
Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting the flu and COVID shots separately, according to the company's results ...
A consistent trend was seen in a subset of adults aged 65 and older Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy ...